General practices (n=61) |
No of GPs | 2.5 (1.4) |
GPs’ professional experience (years) | 14.3 (8.2) |
No of practice assistants | 3.1 (1.4) |
Practice assistants’ professional experience (years) | 10.7 (7.4) |
Practice population size (no of patients per GP) | 1862 (771) |
Time since introduction of spirometry (years) | 4.3 (2.9) |
No of spirometers present | 1.8 (1.2) |
Study subjects (n=388) |
Male/female | 266/122 |
Age (years) | 59.6 (9.7) |
Current smokers, n (%) | 228 (59) |
Cumulative cigarette smoke exposure (pack years) | 28 (17) |
Use of inhaled corticosteroids, n (%) | 58 (15) |
Use of bronchodilator, n (%) | 285 (73) |
FEV1* |
Pre-bronchodilator (l) | 1.80 (0.66) |
% predicted | 60.3 (18.2) |
Post-bronchodilator (l) | 2.00 (0.66) |
% predicted | 66.7 (17.4) |
FVC* |
Pre-bronchodilator (l) | 2.91 (0.92) |
% predicted | 78.2 (18.7) |
Post-bronchodilator (l) | 3.21 (0.94) |
% predicted | 85.9 (18.0) |
FEV1/FVC* |
Pre-bronchodilator (%) | 61.9 (11.7) |
% predicted | 80.5 (14.8) |
Post-bronchodilator (%) | 62.6 (11.6) |
% predicted | 81.3 (14.8) |
Reversibility of FEV1 (%)† | 6.8 (6.2) |